CEO Peter Zerhouni has participated in Pareto Securities’ Healthcare Conference
InDex Pharmaceuticals would like to raise the awareness of World IBD Day by wearing the Purple Ribbon, an international symbol of inflammatory bowel disease (IBD).
Our mission is to significantly improve
the lives of patients suffering from
immunological disorders by providing
effective and safe drugs for diseases
with high unmet medical needs.
Our lead drug candidate
cobitolimod has a new
and unique mechanism of
action to effectively and
safely treat ulcerative colitis.
-
InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021
August 25, 2021 Regulatory
-
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
August 24, 2021 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q2 for January-June 2021 on August 25, 2021 at 08:00 a.m. CEST.
-
CEO Peter Zerhouni presents at Naventus Life Science Summit
-
Interim report Q3 2021
Our upcoming Phase III study CONCLUDE
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis
Proud partner of:
